8-K: OneMedNet Secures $3.7 Million in Private Placement and Converts $6.5 Million in Debt, Significantly Reducing Liabilities

OneMedNet Corporation announced a series of strategic financial transactions, including a $3.7 million private placement and the conversion of approximately $6.5 million in outstanding loans and notes into equity, leading to a 60% reduction in total liabilities.

Summary

• OneMedNet Corporation completed a private placement on June 19, 2025, raising approximately $2.5 million in gross proceeds from an accredited investor.
• The private placement involved the issuance of 3,390,923 shares of common stock and pre-funded warrants to acquire an additional 2,561,457 shares, both at a purchase price of $0.42 per share, with pre-funded warrants exercisable at a nominal $0.0001 per share.
• The company also entered into separate subscription agreements on June 20, 2025, with Dr. Thomas Kosasa (a director) and Dr. Jeffrey Yu (CMO and Chairman), raising an additional $500,000 and $700,000 respectively, through the sale of common stock at $0.42 per share.
• Approximately $3.3 million of outstanding principal and accrued interest from shareholder and business combination extension loans made by Dr. Kosasa and Dr. Yu were converted into 4,693,299 shares of common stock at a conversion price of $0.71 per share.
• An additional approximately $1.6 million in convertible shareholder loans from Dr. Kosasa were converted into 2,123,424 shares of common stock at a conversion price of $0.7535 per share.
• Holders of approximately $1.66 million of PIPE Notes from October 2023 converted their outstanding amounts into 1,453,174 shares of common stock at a conversion price of $1.14 per share.
• The company redeemed for cash the remaining $250,000 outstanding under a convertible promissory note with Yorkville.
• In the second quarter of 2025, the company negotiated and settled approximately $4.34 million of current liabilities, including $2.76 million of deferred underwriter fees payable to EF Hutton.
• Collectively, these actions resulted in the settlement or conversion of approximately $11.0 million of current liabilities, representing a 60.0% reduction in total liabilities outstanding as of March 31, 2025.
• The net proceeds from the private placement and director/CMO investments are intended for general corporate purposes and working capital.

Sentiment

Score: 7

Explanation: The company significantly improved its financial position by raising capital and substantially reducing liabilities, which are strong positive indicators. However, the dilution and the low price of the private placement compared to some debt conversions temper the overall sentiment, suggesting underlying challenges that necessitated these terms.

Positives

• The company successfully raised $3.7 million in cash through a private placement and investments from key management figures, providing crucial working capital.
• OneMedNet significantly reduced its total liabilities by 60.0%, or approximately $11.0 million, as of March 31, 2025, through a combination of debt-to-equity conversions and cash settlements.
• The conversion of approximately $6.5 million in loans and notes into equity strengthens the company's balance sheet by reducing debt obligations and associated interest payments.
• The participation of a director (Dr. Kosasa) and the Chief Medical Officer and Chairman (Dr. Yu) in both new investments and loan conversions demonstrates management's confidence in the company's future.

Negatives

• The private placement and other equity issuances will result in significant dilution for existing shareholders, with approximately 17.07 million new shares issued or issuable.
• The purchase price of $0.42 per share in the private placement and director/CMO investments is substantially lower than some of the debt conversion prices ($0.71, $0.7535, $1.14), potentially indicating a distressed capital raise or a significant discount for new money.
• The registration statement for the resale of the newly issued shares and warrant shares is not yet effective, meaning investors cannot immediately resell these securities, which could impact liquidity.
• The private placement investor is subject to a 120-day lock-up period, restricting their ability to sell or hedge their shares.

Risks

• The resale of shares issued in the private placement and loan conversions is contingent on an amendment to the company's most recent registration statement on Form S-1 being declared effective by the SEC, which has not yet occurred.
• The shares issued are unregistered and subject to resale restrictions under federal and state securities laws, limiting liquidity for investors.
• The private placement investor is subject to a Beneficial Ownership Limitation of 9.99% of outstanding common stock, which restricts their ability to exercise warrants or acquire additional shares if it would exceed this threshold.
• The company's ability to increase authorized common stock for warrant exercises depends on shareholder approval if current authorized shares are insufficient.

Future Outlook

The company intends to use the net proceeds from the private placement and related investments for general corporate purposes and working capital. The company also committed to registering the resale of the newly issued shares and shares underlying the pre-funded warrants on an amendment to its most recent registration statement on Form S-1, which has not yet been declared effective by the SEC.

Management Comments

• Aaron Green, Chief Executive Officer, signed the Form 8-K on behalf of OneMedNet Corporation.
• Dr. Thomas Kosasa, a director, and Dr. Jeffrey Yu, the Chief Medical Officer and Chairman, participated in significant investments and loan conversions, indicating their commitment to the company.

Industry Context

This announcement primarily details a significant capital restructuring and debt reduction effort by OneMedNet Corporation. While the document does not provide specific industry trends or competitive analysis, these financial maneuvers are common for companies seeking to strengthen their balance sheets, improve liquidity, and fund operations, particularly in growth-oriented or capital-intensive sectors like healthcare technology or medical imaging, where OneMedNet operates.

Comparison to Industry Standards

• The private placement price of $0.42 per share, while providing capital, is notably lower than the conversion prices for some of the converted debt ($0.71, $0.7535, $1.14 per share). This disparity could suggest a significant discount offered to new investors for fresh capital, which is not uncommon in challenging market conditions or for companies in need of immediate liquidity, but it is a point of concern compared to typical equity raises by more stable, established industry players.
• The 60% reduction in total liabilities is a substantial improvement to the balance sheet, which could be viewed favorably compared to industry peers struggling with high debt loads. This level of debt reduction is a strong indicator of financial de-risking.
• The use of pre-funded warrants with a nominal exercise price is a common mechanism in private placements to manage beneficial ownership limitations for large investors while still providing immediate capital to the company, aligning with standard practices for such transactions.

Corporate Governance

Related Party Transactions

• Dr. Thomas Kosasa, a director, invested $500,000 for 1,190,476 shares of common stock at $0.42 per share.
• Dr. Jeffrey Yu, the Chief Medical Officer and Chairman, invested $700,000 for 1,666,666 shares of common stock at $0.42 per share.
• Dr. Kosasa and Dr. Yu converted approximately $3.3 million of outstanding shareholder and business combination extension loans into 4,693,299 shares of common stock at $0.71 per share.
• Dr. Kosasa converted approximately $1.6 million of convertible shareholder loans into 2,123,424 shares of common stock at $0.7535 per share.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience significant dilution due to the issuance of new shares and warrant shares. However, the reduction in liabilities and improved liquidity could stabilize the company's financial position, potentially benefiting long-term shareholder value.
• **Creditors**: Creditors whose loans were converted into equity will no longer hold debt claims against the company, reducing the company's financial obligations. Those whose payables were settled will receive payment.
• **Employees**: Improved financial stability from reduced liabilities and increased working capital could provide greater job security and operational continuity.

Next Steps

• The company is required to register the resale of the newly issued shares and shares underlying the pre-funded warrants on an amendment to its most recent registration statement on Form S-1.
• The settled liabilities will be reflected in the company's financial results for the quarter ended June 30, 2025.

Key Dates

Recommendation

Keywords

Private Placement, Debt Conversion, Capital Raise, SEC Filing, Form 8-K, Equity Issuance, Pre-Funded Warrants, Liability Reduction, Corporate Finance, Shareholder Loans, PIPE Notes, OneMedNet Corporation